Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGAV | P06756 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716729 | 0.74 | PGR (0.45) | PGRSCN1ASCN2ASCN3ALMNA | |
| SCHEMBL6716864 | 0.73 | PGR (0.47) | PGRSCN1ASCN2ASCN3ALMNA | |
| SCHEMBL6723693 | 0.73 | KMT2A (0.43) | KMT2AMEN1PGRSCN1ASCN2A | |
| SCHEMBL6715549 | 0.71 | CYP1A2 (0.46) | PGRSCN1ASCN2ASCN3ALMNA | |
| SCHEMBL6714213 | 0.69 | POLB (0.39) | KMT2AMEN1LMNAMAPTPOLB | |
| SCHEMBL6824939 | 0.69 | POLB (0.46) | KMT2APGRSCN1ASCN2ASCN3A | |
| SCHEMBL6717476 | 0.69 | MAPT (0.41) | KMT2AMEN1LMNAMAPTGAA | |
| SCHEMBL6825272 | 0.69 | CYP1A2 (0.51) | KMT2APGRSCN1ASCN2ASCN3A | |
| SCHEMBL11136745 | 0.67 | MEN1 (0.59) | KMT2AMEN1PGRSCN1ASCN2A | |
| SCHEMBL748999 | 0.66 | PGR (0.44) | PGRLMNAGAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | KMT2A 2020/4885MEN1 2933/4885PGR 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.